Switzerland Archives

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jan 2016

BioArt in Berlin: Making Dystopia Beautiful with Prostheses and the Transhuman Life

I met the curators of a BioArt Gallery in Berlin very recently and they invited me to their latest of exhibition ‘Prostheses: Transhuman Life’ by the Artist Susanna Hertrich. The exhibition, hosted by Christian De Lutz and Regine Rapp (the wonderfully warm curators of Art Laboratory Berlin) presented ‘wearable tech’ devices made to trigger emotions, […]

January 8, 2016 - 4 minutesmins - By Dani Bancroft

crispr bayer therapeutics genetic disease joint venture london

News and Trends 22 Dec 2015

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Blood disorders, blindness and congenital heart disease? The new Bayer Life Science Center (BLSC) in Germany and CRISPR Therapeutics (Switzerland) have now created a joint Venture to tackle cures for these rare genetic defects. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise […]

December 22, 2015 - 2 minutesmins - By Dani Bancroft

hypoxia cancer hpv inthera aglaia oncology

News and Trends 17 Dec 2015

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

The Dutch Oncology VC Specialist Aglaia has invested €3.4M in the Swiss Start-Up Inthera Bioscience for their Small molecule platform against solid tumors. Aglaia is a venture capital firm based in Bilthoven (NL) which has 3 funds under their management for specialist investment into Oncology research. Last year they raised over €50M as part of […]

December 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Dec 2015

World’s First Microbiome Fund Swells to €160M With Major Pharma Also Chipping In

The French VC firm Seventure‘s Health for Life Capital investment fund for Microbiome and Biotech has had an additional €60M pumped into it by Swiss Pharma Giant Novartis and other investors. Health for Life Capital is the first and unique microbiome focused investment vehicle. Now it has been announced that Novartis and other investors have also become […]

December 14, 2015 - 2 minutesmins - By Dani Bancroft

roche cellsqueeze sqz cell therapies Cancer

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now acquired this small biotech for €455M upfront. MIT Professors Klavs Jensen, Robert Langer and PhD Student Armon Sharei were focused on developing a more effective system for […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Dec 2015

Rare Diseases: Still a ‘Blue Ocean’ for Biotechs?

We all know the success stories linked to Rare Disease such as Genzyme. But I wanted to get a deeper understanding on what is today considered as Rare disease, who is acting the field and the reasons for so many Biotech companies to dive into the field. Last week was the RARE 2015 congress in […]

December 1, 2015 - 6 minutesmins - By Philip Hemme

nanomedicine cubosomes nestle epfl cime coimbra

News and Trends 18 Nov 2015

Nanomedicine Inside Out: A Nestlé Advance in Cuboid Drug Delivery Systems

A New feat in Nanomedicine: The Cubosome drug delivery system has now been 3D-mappped and studied internally by Scientists from the Swiss Federal Institute of Technology (EPFL) and University of Coimbra (Portugal) at the Nestlé Research Center in Lausanne (Switzerland). What are Cubosomes? These small nanostructures are ‘crystalline liquid phases’ engineered in bulk to hold […]

November 18, 2015 - 3 minutesmins - By Dani Bancroft

swissmedic newron xadago zambon parkinsons

News and Trends 16 Nov 2015

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s Disease. Zambon, is a Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases. Its partner, Newron Pharmaceuticals, is a research and development biotech from northern […]

November 16, 2015 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

BioArt in Berlin: Making Dystopia Beautiful with Prostheses and the Transhuman Life

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

World’s First Microbiome Fund Swells to €160M With Major Pharma Also Chipping In

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

Rare Diseases: Still a ‘Blue Ocean’ for Biotechs?

Nanomedicine Inside Out: A Nestlé Advance in Cuboid Drug Delivery Systems

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!